1. Home
  2. NBIX vs BMRN Comparison

NBIX vs BMRN Comparison

Compare NBIX & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$130.52

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Logo BioMarin Pharmaceutical Inc.

BMRN

BioMarin Pharmaceutical Inc.

HOLD

Current Price

$54.13

Market Cap

10.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBIX
BMRN
Founded
1992
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
10.5B
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
NBIX
BMRN
Price
$130.52
$54.13
Analyst Decision
Strong Buy
Buy
Analyst Count
22
18
Target Price
$180.91
$88.22
AVG Volume (30 Days)
1.1M
1.4M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
41.95
N/A
EPS
4.67
1.80
Revenue
$161,626,000.00
$1,313,646,000.00
Revenue This Year
$24.73
$15.02
Revenue Next Year
$13.14
$12.23
P/E Ratio
$27.99
$30.12
Revenue Growth
977.51
17.62
52 Week Low
$107.96
$50.76
52 Week High
$160.18
$66.28

Technical Indicators

Market Signals
Indicator
NBIX
BMRN
Relative Strength Index (RSI) 51.13 44.83
Support Level $124.62 $53.45
Resistance Level $135.88 $56.21
Average True Range (ATR) 3.58 1.34
MACD -0.12 -0.01
Stochastic Oscillator 59.98 46.37

Price Performance

Historical Comparison
NBIX
BMRN

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Share on Social Networks: